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ABSTRACT
Objectives: Intercountry comparability between
studies on medication use in pregnancy is difficult due
to dissimilarities in study design and methodology.
This study aimed to examine patterns and factors
associated with medications use in pregnancy from a
multinational perspective, with emphasis on type of
medication utilised and indication for use.
Design: Cross-sectional, web-based study performed
within the period from 1 October 2011 to 29 February
2012. Uniform collection of drug utilisation data was
performed via an anonymous online questionnaire.
Setting: Multinational study in Europe (Western, Northern
and Eastern), North and South America and Australia.
Participants: Pregnant women and new mothers with
children less than 1 year of age.
Primary and secondary outcome measures:
Prevalence of and factors associated with medication use
for acute/short-term illnesses, chronic/long-term disorders
and over-the-counter (OTC) medication use.
Results: The study population included 9459 women,
of which 81.2% reported use of at least one medication
(prescribed or OTC) during pregnancy. Overall, OTC
medication use occurred in 66.9% of the pregnancies,
whereas 68.4% and 17% of women reported use of at
least one medication for treatment of acute/short-term
illnesses and chronic/long-term disorders, respectively.
The extent of self-reported medicated illnesses and types
of medication used by indication varied across regions,
especially in relation to urinary tract infections, depression
or OTC nasal sprays. Women with higher age or lower
educational level, housewives or women with an unplanned
pregnancy were those most often reporting use of
medication for chronic/long-term disorders. Immigrant
women in Western (adjusted OR (aOR): 0.55, 95% CI 0.34
to 0.87) and Northern Europe (aOR: 0.50, 95% CI 0.31 to
0.83) were less likely to report use of medication for
chronic/long-term disorders during pregnancy than non-
immigrants.
Conclusions: In this study, the majority of women in
Europe, North America, South America and Australia used
at least one medication during pregnancy. There was a
substantial inter-region variability in the types of medication
used.
INTRODUCTION
Ethical reasons preclude inclusion of preg-
nant women in the vast majority of premar-
keting clinical trials.1 As a consequence, most
medications are placed onto the market
without a directly established safety proﬁle in
human pregnancy.2 So far, few medications
have been shown to be major teratogens, yet
the risk of minor teratogenicity or of more
subtle effects on fetal development still have
to be determined for most of them.3 Despite
this, medication use during pregnancy is
common. Mitchell et al4 found that use of
medications, either prescribed or purchased
over the counter (OTC), occurred in 88.8%
of all pregnancies in the USA. In Europe,
prevalence estimates of prescribed medica-
tion use vary considerably across countries,
ranging from 26% in Serbia to 93% in
France.5–10 Such intercountry variability
could, at least in part, be caused by
Strengths and limitations of this study
▪ Uniform data collection of drug utilisation data
across all participating countries allows for inter-
country comparability of the prevalence of medi-
cation use during pregnancy, up to now impeded
by differences in study design and methodology.
▪ The study adds a multinational perspective on
over-the-counter medication use during preg-
nancy to the limited number of studies quantify-
ing the extent of self-medication during
pregnancy.
▪ Lack of validity of the self-reported diagnoses is
a limitation since all disorders and related medi-
cation use were self-reported by the study
participants.
▪ A web-based survey as a study method impedes
calculation of a conventional response rate and
may cause selection bias of the target
population.
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differences in study design, methodology and exposure
ascertainment across studies.11 Uniform collection of
drug utilisation data during pregnancy between coun-
tries may overcome such drawbacks, allowing for inter-
country comparability of prevalence estimates and
shedding light on differences in prenatal care in the
various countries.
Prior studies have addressed research priorities in this
area such as presenting results on an individual drug
level according to the indication of use, quantifying the
extent of OTC and prescribed medication use during
pregnancy, and taking into account intercountry com-
parability.4 Only a few studies have individually examined
maternal factors associated with speciﬁc types of medica-
tion use during pregnancy.11–14
The objectives of the current study were to examine
patterns of medication use in pregnancy from a multi-
national perspective, with special emphasis on type of
medication utilised, including OTC medications and
self-reported indications for use, and to identify mater-
nal background factors potentially associated with medi-
cation use for acute/short-term illnesses, medication use
for chronic/long-term disorders and OTC medication
use during pregnancy.
METHODS
Study design and data collection
This is a multinational, cross-sectional, web-based study.
Pregnant women at any gestational week and mothers with
children less than 1 year of age were eligible to participate.
Member countries of the European Network of Teratology
Information Services (ENTIS), the Organization of
Teratology Information Specialists (OTIS) in North
America, MotherSafe in Australia and European institu-
tions conducting public health research were invited to
take part in the project. Of these, 18 countries participated
(Australia, Austria, Canada, Croatia, Finland, France,
Iceland, Italy, the Netherlands, Norway, Poland, Russia,
Serbia, Slovenia, Sweden, Switzerland, the UK and the
USA). Data originating from some South and Central
American countries were also collected through OTIS.
Owing to the low number of participants on the individual
country level, the region of Central America was excluded
and countries in South America were aggregated into one
region. Data selection to achieve the ﬁnal study sample
was performed as depicted in ﬁgure 1. Participants were
categorised according to the reported country of residency
and grouped into six regions: Western Europe, Northern
Europe, Eastern Europe, North America, South America
and Australia.
Data were collected through an anonymous online
questionnaire administered by Quest Back (http://www.
questback.com) and accessible for a period of 2 months
in each participating country within the period 1
October 2011 to 29 February 2012. The questionnaire
was open to the public via utilisation of banners (invita-
tions to participate in the study) on national websites
and/or social networks commonly visited and consulted
by pregnant women and/or new mothers. The complete
questionnaire is presented in online supplementary
appendix 1. Detailed information about recruitment
tools utilised and Internet penetration rates are sum-
marised in online supplementary appendix 2.
The questionnaire was ﬁrst developed in Norwegian
and English and then translated into the other relevant
languages. A pilot study was carried out in September
2011 (n=47) which elicited no major change to the
questionnaire. Collected data were scrutinised for the
presence of potential duplicates (based on reported
country of residency, sociodemographic characteristics,
date and exact time of questionnaire completion) but
none were identiﬁed.
Exposure variables
Maternal sociodemographics (ie, region of residency,
age, educational level, mother tongue, working status at
time of conception, previous children, marital status and
unplanned pregnancy) and lifestyle characteristics (ie,
smoking status before and during pregnancy and
alcohol consumption after awareness of pregnancy) con-
stituted the exposure variables. To assess external valid-
ity, we compared sociodemographic and lifestyle
characteristics of our study population on an individual
country level with those of the general birthing popula-
tion in the same country. Reports of National Statistics
Bureaus or previous national studies were utilised for
this purpose. The ratio between the number of respon-
dents and the estimated number of live births in the
2-month period was also examined for each country (see
online supplementary appendix 3).
Outcome variables
Use of any medication, medication for acute/short-term
illnesses, medication for chronic/long-term disorders
and OTC medication use during pregnancy constituted
the outcome variables. Participants were ﬁrst confronted
with a list of the most common acute/short-term ill-
nesses (ie, nausea, heartburn, constipation, common
cold, urinary tract infections (UTIs), other infections,
pain in the neck/back/pelvic girdle, headache and
sleeping problems) and the most prevalent chronic/
long-term disorders (ie, asthma, allergy, hypothyroidism,
rheumatic disorders, diabetes, epilepsy, depression,
anxiety, cardiovascular disease and other disorders) and
asked whether they suffered/had suffered from these
conditions during pregnancy. In case of an afﬁrmative
response, women were questioned about medication use
for each individual indication as a free-text entry. Use of
OTC medications was also recorded. Recall was aided
with a list of ﬁve OTC medication categories: painkillers,
nasal spray/drops, antinauseants, antacids and laxatives,
along with examples of brand name products of rele-
vance in each country. It was optional to report timing
of exposure for each of the medication use questions
(the alternatives were gestational weeks 0–12 (1st
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trimester), 13–24 (2nd trimester) and 25 to delivery
(3rd trimester)).
We deﬁned a medicine as a single product containing
one or more active ingredients. We initially identiﬁed
the main active ingredient(s) and formulation of the
reported medicinal products either in the relevant
national medicines database or in the ‘Martindale’ text-
book.15 All recorded medications were coded into the
corresponding Anatomical Therapeutic Chemical (ATC)
codes at the ATC 5th level (ie, the substance level)
whenever possible, otherwise into the 2nd–4th levels as
appropriate, in accordance with the WHO ATC index.16
The OTC status of medications was crosschecked with
the prescription policies within each country. Whenever
a prescription medication was reported under the OTC
question, this record was omitted from the analysis of
OTC use but counted in the estimation of total medica-
tion use (including prescription and OTC). Iron,
mineral supplements, vitamins, herbal remedies and any
type of complementary medicine were recorded separ-
ately and excluded from the estimation of medication
use.
The required sample size calculation for the outcome
variables on region and individual country levels is out-
lined in online supplementary appendix 4. The expected
prevalence estimates were set according to the results of
previous studies.5–10 17 18
Ethics
All participants gave informed consent by answering
‘Yes’ to the question ‘Are you willing to participate in
the study?’. All data were handled and stored
anonymously.
Statistical analysis
Descriptive statistics were utilised as appropriate.
Univariate and multivariate logistic regression analyses
were used to examine the association between maternal
characteristic and three categorical outcome measures
(yes/no): medication use for acute/short-term illnesses;
medication use for chronic/long-term disorders; OTC
medication use. p Values of <0.05 were considered statis-
tically signiﬁcant. Data are presented as adjusted ORs
(aOR) with 95% CI. The analysed explanatory variables
included all maternal sociodemographics and lifestyle
characteristics. After ﬁtting the univariate logistic regres-
sion model for all explanatory variables, the multivariate
model was built and adjusted for all remaining covari-
ates. The Hosmer and Lemeshow19 test was used to
assess goodness of ﬁt of the ﬁnal multivariate model.
Analogue subanalyses on individual region level were
performed. In these instances, region of residency was
not included in the model. All statistical analyses were
performed using the Statistical Package for the Social
Sciences (SPSS) V.20.0 (IBM SPSS Statistics).
RESULTS
Population characteristics
A total of 9615 women accessed the online question-
naire, of which 98.6% completed it. The participant
ﬂowchart to achieve ﬁnal study population (n=9459) is
depicted in ﬁgure 1. A total of 5089 women (53.8%)
Figure 1 The participant flowchart to achieve the final sample analysed.
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were pregnant at the time of completion of the ques-
tionnaire, whereas 4370 women (46.2%) had delivered
their babies within the previous year. Of the former
group, 1095 (21.5%), 1702 (33.4%) and 2291 (45%)
women were in the ﬁrst, second and third trimester of
pregnancy, respectively. Of the latter group, 1320
(30.2%), 947 (21.7%) and 2102 (48.1%) had a baby of
age ≤16 weeks, 17–28 weeks and ≥29 weeks, respectively.
For two women, the time of gestation/baby’s age was
unknown. Overall, the birthing population in each par-
ticipating country was reﬂected quite well by the sample
with respect to age, parity and smoking habits (see
online supplementary appendix 3). However, there was
a difference in terms of educational level; on average,
the women in the study had higher education than the
general birthing population in each country. In add-
ition, participants in Sweden, Austria, Iceland and Italy
were slightly more often primiparous, whereas the
responders in Australia, the USA, the Netherlands,
Slovenia and Croatia were somewhat older than the
general birthing population.
Total medication use
After exclusion of vitamins, mineral supplements and
iron, use of at least one medication either prescribed or
OTC at any time during pregnancy was reported by
7678 of 9459 women (81.2%). Figure 2 depicts preva-
lence estimates of total medication use during
pregnancy by region and country of residence. The
extent of OTC medication use, as well as medication use
for acute/short-term illnesses and chronic/long-term
disorders, is also outlined. The highest prevalence of
total medication use during pregnancy was observed in
the Netherlands (95.1%), Iceland (93%) and Finland
(92.3%). The overall prevalence estimates of medication
use in pregnancy according to timing and drug class
(ATC levels 1 and 2) are presented in online supplemen-
tary appendix 5. Medications for the nervous system
(ATC class N) were most commonly used during preg-
nancy (57.5%), mostly due to paracetamol (acetamino-
phen) and its combinations.
A corollary analysis according to pregnancy status
showed that pregnant women reported in a signiﬁcantly
lower degree than new mothers any medication use
during pregnancy (78.8% vs 84%, p<0.001), as well as
OTC medication use (63% vs 71.5%, p<0.001) and
medication use for acute/short-term illnesses (66.2% vs
70.9%, p<0.001). In contrast, the difference in medica-
tion use for chronic/long-term disorders was not signiﬁ-
cant (17.4% vs 16.5%, p=0.271). None of the rates
differed signiﬁcantly when women in the third trimester
of pregnancy were compared with new mothers.
Medication use according to indication
Headache, heartburn, pain, nausea and UTIs consti-
tuted the leading indications for use of medication
Figure 2 The proportion of respondents (%) reporting use of any medication, over-the-counter (OTC) medication, medication for
acute/short-term illnesses and medication for chronic/long-term disorders during pregnancy, according to region and country of
residency. The observed estimates do not include vitamins, mineral supplements, iron and herbal or complementary medicine
products.
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during pregnancy among the acute/short-term illnesses
analysed. Hypothyroidism, asthma, allergy and depres-
sion were the leading indications for chronic/long-term
medication use. Observed prevalence rates of these dis-
orders, overall and by region of residency, are presented
in online supplementary appendices 6 and 7, respect-
ively, along with rates of total and speciﬁc medication
use. Table 1 outlines prevalence estimates of OTC medi-
cation use during pregnancy by region and indication
for use. Only the most common medication groups
reported are presented. Inter-region variations in rates
and types of medication used during pregnancy were
observed for acute/short-term illnesses (eg, nausea and
UTIs), chronic/long-term disorders (eg, asthma and
depression) and OTC medications (eg, nasal spray).
Factors associated with medication use
Factors associated with medication use during pregnancy
according to type of medication utilised are presented
in table 2. Use of chronic/long-term medications during
pregnancy was reported in a signiﬁcantly larger extent
by women in Northern Europe (aOR: 1.68, 95% CI 1.46
to 1.94), North America (aOR: 1.80, 95% CI 1.42 to
2.28) and Australia (aOR: 2.76, 95% CI 2.03 to 3.76)
compared with women in Western Europe. Older
women or housewives, those with low education or with
an unplanned pregnancy, were the ones most often
reporting use of chronic/long-term medication.
Subanalysis on individual region level revealed that
women not having the ofﬁcial language of the country
of residency as mother tongue were less likely to report
chronic/long-term medication use in Western (aOR:
0.55, 95% CI 0.34 to 0.87) and Northern Europe (aOR:
0.50, 95% CI 0.31 to 0.83), but not in the other regions.
DISCUSSION
This is the ﬁrst web-based study examining patterns and
factors associated with medication use during pregnancy
on a multinational level. In all regions, approximately 8
of 10 women reported use of at least one medication,
either prescribed or OTC, during the course of their
pregnancy. This ﬁnding is in line with previous research
conducted in Europe, North America, South America
and Australia,4 20–25 though our estimates were some-
what higher in some of the Eastern European countries,
for example, Serbia, than those observed in a previous
study.5 Different recruitment strategies, that is, web
based in our study versus maternity care unit/commu-
nity pharmacy based in the previous study could explain
such discrepancy.
Overall, analgesics, antacids, nasal decongestants/anti-
allergics and systemic antibiotics were the medication
groups dominating the drug utilisation scenario, as also
shown by previous research.4 20–22 However, our study
also provides insights into the proportion of medicated
women among those suffering from a speciﬁc illness
during pregnancy across the six regions. We found that
approximately 7 of 10 women who reported UTIs were
treated with antibiotics during pregnancy. This related
to all regions, except Eastern Europe where it was only 4
of 10 women. Since women may perceive dysuria
without ascertainment of bacteriuria in the urine as
UTI, an over-reporting of the illness could have
occurred. Yet, a suboptimal treatment of UTIs during
pregnancy in Eastern Europe cannot be ruled out. The
intercountry variability in the types of antibiotics used
for UTIs could simply be explained by differences in
prescribing practice,26 presence of screening for bacteri-
uria in early pregnancy or speciﬁc antibiotic resistance
patterns.
Even though nausea was the condition affecting most
women in all six regions, the corresponding proportions
of medicated nausea were generally low. This scenario is
probably due to two main factors: (1) the predominantly
mild character of nausea and the possibility of non-
pharmacological management (eg, dietary advices) and
(2) the reluctance of general practitioners to prescribe
antinauseants even though safety proﬁle assessments are
in place.27 28 As also shown in previous studies,4 29 use of
serotonin antagonists during pregnancy in North America
and Australia is increasing compared with the other
regions, eliciting the need of sound studies assessing the
safety proﬁle of this drug group in pregnancy.
In most regions, the self-reported prevalence of hypo-
thyroidism was somewhat higher than the reported
hormone substitution rate. Owing to its known associ-
ation with adverse pregnancy outcomes,30 the unex-
pected ﬁnding of potential suboptimal treatment of
hypothyroidism during pregnancy deserves attention. It
could probably be due to lack of information about
hypothyroidism typology and its diagnostic ascertain-
ment in our study.
In our study, depression was self-reported and not
based on any psychometric assessment, thus the
observed substantial inter-regional variability in the
extent of this disorder and related medication use could
have certainly been affected by women’s attitudes in
reporting. Our estimate of medication use for depres-
sion in Australia was higher than that observed in a
recent study (10.6% vs 2.1%).31 However, the similarity
in self-reported depression itself (11.5% vs 15.6%) sug-
gests that our population might mostly comprise women
who did not discontinue their pharmacological therapy
once they became pregnant. Our estimates for North
America and Western Europe were in line with recent lit-
erature showing an increase in antidepressant use in
pregnancy during the past years.4 32 Selective serotonin
reuptake inhibitors (SSRIs) were the most widely used
antidepressant class. Recent meta-analyses have shown
that antidepressants, including SSRIs, do increase the
risk of poor neonatal adaptation syndrome, speciﬁc car-
diovascular malformations and persistent pulmonary
hypertension of the newborn.33–35 However, the clinical
impact of the latter two outcomes, in absolute terms, is
small and the risk of pharmacotherapy should always be
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Table 1 Use of OTC medication at any time during pregnancy by ATC level, indication for use and region (n=9459)*†
OTC medication use, overall and by drug groups REGION
Total
n=9459
n (%)
Western
Europe
n=3201
n (%)
Northern
Europe
n=2820
n (%)
Eastern
Europe
n=2342
n (%)
North
America
n=533
n (%)
South
America
n=346
n (%)
Australia
n=217
n (%)
OTC painkillers, total 1714 (53.5) 1773 (62.9) 734 (31.3) 284 (53.3) 127 (36.7) 151 (69.9) 4783 (50.6)
By drug group
Paracetamol (including combinations) (N02BE) 1655 (51.7) 1735 (61.5) 630 (26.9) 263 (49.3) 87 (25.1) 146 (67.3) 4516 (47.7)
Non-steroidal anti-inflammatory drugs (M01A) 70 (2.2) 182 (6.5) 68 (2.9) 40 (7.5) 59 (17.1) 7 (3.2) 426 (4.5)
Acetylsalicylic acid (including combinations)
(N02BA)
7 (0.2) 11 (0.4) 32 (1.4) 2 (0.4) 2 (0.6) 1 (0.5) 55 (0.6)
Metamizole (N02BB02) – 6 (0.2) 31 (1.3) 1 (0.2) 12 (3.5) – 50 (0.5)
OTC antacids, total 1011 (31.6) 883 (31.3) 583 (24.9) 129 (24.2) 48 (13.9) 76 (35.0) 2730 (28.9)
By drug group
Antacids (aluminium, salts combinations,
antiflatulents)
472 (14.7) 550 (19.5) 508 (21.7) 47 (8.8) 36 (10.4) 54 (24.9) 1667 (17.6)
Alginic acid complex/sucralfate/bismuth (A02BX) 606 (18.9) 421 (14.9) 87 (3.7) 4 (0.8) 1 (0.3) 17 (7.8) 1136 (12.0)
H2 receptor antagonists (A02BA) 20 (0.6) 20 (0.7) 16 (0.7) 57 (10.1) 10 (2.9) 17 (7.8) 137 (1.4)
Antacids with calcium (A02AC) 23 (0.7) 12 (0.4) 10 (0.4) 69 (12.9) 2 (0.6) 10 (4.6) 126 (1.3)
Proton pump inhibitors (A02BC) 38 (1.2) 52 (1.8) – 10 (1.9) 2 (0.6) 5 (0.3) 107 (1.1)
OTC nasal sprays/drops, total 272 (8.5) 742 (26.3) 451 (19.3) 35 (6.6) 7 (2.0) 14 (6.5) 1521 (16.1)
By drug group
Sympathomimetic nasal decongestants (R01AA/
R01BB)
204 (6.4) 683 (24.2) 365 (15.6) 20 (3.8) 3 (0.9) 4 (1.8) 1279 (13.5)
Nasal corticosteroids (R01AD) 31 (1.0) 49 (1.7) 12 (0.5) 5 (0.9) 2 (0.6) 10 (4.6) 109 (1.2)
Nasal immunostimulants (low-dose interferon)
(L03A)
– – 28 (1.2) – – – 28 (0.3)
OTC laxatives, total 240 (7.5) 227 (8.0) 237 (10.1) 50 (9.4) 8 (2.3) 19 (8.8) 781 (8.3)
By drug group
Osmotically acting laxatives (A06AD) 159 (5.0) 171 (6.1) 197 (8.4) 2 (0.4) 2 (0.6) 8 (3.7) 539 (5.7)
Contact laxatives (A06AB) 28 (0.9) 44 (1.6) 18 (0.8) 7 (1.3) 6 (1.7) 2 (0.9) 105 (1.1)
Enemas (A06AG) 3 (0.1) 25 (0.9) 34 (1.5) 4 (0.8) – 2 (0.9) 68 (0.7)
Softeners, emollients (A06AA) 8 (0.2) – – 38 (7.1) – 6 (2.8) 52 (0.5)
OTC antinauseants, total 263 (8.2) 273 (9.7) 41 (1.8) 60 (11.3) 28 (8.1) 40 (18.4) 705 (7.5)
By drug group
First generation antihistamines (R06A) 141 (4.4) 256 (9.1) 7 (1.5) 55 (10.3) 5 (1.4) 5 (2.3) 469 (5.0)
Metoclopramide/domperidone/bromopride (A03FA) 113 (3.5) 5 (0.2) 18 (0.8) 2 (0.4) 19 (5.5) 27 (12.4) 184 (1.9)
Total OTC medication use 2163 (67.6) 2155 (76.4) 1347 (57.5) 342 (64.2) 156 (45.1) 168 (77.4) 6331 (66.9)
*Countries are grouped into regions as shown in figure 1.
†Sums of percentages do not add up to total medication use as only most common medication groups are presented. Rates do not include mineral supplements, vitamins, iron and herbal or
complementary medicine products.
Total use estimates of the main OTC categories are presented in italics.
ATC, Anatomical Therapeutic Chemical; OTC, over-the-counter medications.
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Table 2 Factors associated with medication use in pregnancy (n=9459)*
Medication use
For acute/short-term illnesses
(n=6469)
For chronic/long-term disorders
(n=1604) OTC (n=6331)
n (%) aOR (95% CI) n (%) aOR (95% CI) n (%) aOR (95% CI)
Region of residency†
Western Europe 2224 (69.5) Reference 462 (14.4) Reference 2163 (67.6) Reference
Northern Europe 1954 (69.3) 0.96 (0.86 to 1.08) 593 (21.0) 1.68 (1.46 to 1.94) 2155 (76.4) 1.54 (1.36 to 1.74)
Eastern Europe 1474 (62.9) 0.69 (0.61 to 0.78) 322 (13.7) 1.03 (0.87 to 1.21) 1347 (57.5) 0.60 (0.53 to 0.67)
North America 403 (75.6) 1.28 (1.03 to 1.60) 119 (22.3) 1.80 (1.42 to 2.28) 342 (64.2) 0.81 (0.66 to 0.99)
South America 250 (82.3) 1.03 (0.79 to 1.34) 38 (11.0) 0.70 (0.48 to 1.01) 156 (45.1) 0.34 (0.27 to 0.44)
Australia 164 (75.6) 1.29 (0.93 to 1.79) 70 (32.3) 2.76 (2.03 to 3.76) 168 (77.4) 1.57 (1.12 to 2.20)
Maternal age (years)
≤20 232 (70.5) 1.22 (0.93 to 1.60) 761 (14.7) 0.58 (0.39 to 0.87) 205 (62.3) 1.05 (0.81 to 1.36)
21–30 3531 (68.2) Reference 33 (10.0) Reference 3461 (66.8) Reference
31–40 2576 (68.6) 0.90 (0.82 to 1.00) 764 (20.4) 1.44 (1.27 to 1.63) 2531 (67.4) 0.85 (0.77 to 0.94)
≥41 130 (66.3) 0.73 (0.54 to 1.00) 46 (23.5) 1.61 (1.13 to 2.29) 134 (68.4) 0.86 (0.62 to 1.19)
Previous children
No 3082 (65.5) Reference 735 (15.6) Reference 2949 (62.6) Reference
Yes 3387 (71.3) 1.34 (1.22 to 1.47) 869 (18.3) 1.08 (0.96 to 1.21) 3382 (71.2) 1.58 (1.44 to 1.74)
Marital status
Married/cohabiting 6066 (68.5) Reference 1503 (17.0) Reference 5960 (67.3) Reference
Single/divorced/others 403 (66.3) 0.91 (0.75 to 1.10) 101 (16.6) 1.06 (0.83 to 1.35) 371 (61.0) 0.91 (0.75 to 1.10)
Working status
Employed, but not as HCP 3737 (66.8) Reference 905 (16.2) Reference 3667 (65.6) Reference
HCP 934 (74.4) 1.41 (1.23 to 1.63) 240 (19.1) 1.13 (0.96 to 1.33) 944 (75.2) 1.42 (1.23 to 1.64)
Student 592 (69.1) 1.11 (0.94 to 1.31) 128 (14.9) 1.04 (0.84 to 1.30) 578 (67.4) 1.10 (0.93 to 1.30)
Housewife 608 (72.6) 1.14 (0.96 to 1.35) 170 (20.3) 1.34 (1.10 to 1.63) 577 (68.9) 1.05 (0.88 to 1.24)
Job seeker 281 (66.0) 0.96 (0.78 to 1.20) 66 (15.5) 1.03 (0.78 to 1.36) 258 (60.6) 0.85 (0.68 to 1.05)
Other than above 311 (65.2) 0.91 (0.75 to 1.12) 94 (19.7) 1.29 (1.01 to 1.65) 302 (63.3) 0.91 (0.74 to 1.12)
Educational level
Less than high school 331 (72.7) 1.17 (0.93 to 1.49) 92 (20.2) 1.51 (1.15 to 1.97) 317 (69.7) 1.32 (1.04 to 1.67)
High school 1864 (68.7) Reference 428 (15.8) Reference 1779 (65.6) Reference
More than high school 3574 (68.4) 0.99 (0.89 to 1.11) 916 (17.5) 1.04 (0.91 to 1.20) 3489 (66.8) 1.07 (0.96 to 1.19)
Others, unspecified 700 (65.7) 0.82 (0.70 to 0.96) 168 (15.8) 0.94 (0.77 to 1.16) 746 (70.0) 1.13 (0.97 to 1.33)
Alcohol use after awareness of pregnancy
No 5270 (67.1) Reference 1322 (16.8) Reference 5133 (65.3) Reference
Yes 1144 (75.7) 1.59 (1.39 to 1.81) 270 (17.9) 1.11 (0.95 to 1.29) 1150 (76.1) 1.95 (1.71 to 2.23)
Smoking during pregnancy
No 5835 (68.5) Reference 1441 (16.9) Reference 5716 (67.0) Reference
Yes, but less than before pregnancy 530 (69.0) 1.08 (0.91 to 1.27) 130 (16.9) 1.01 (0.82 to 1.25) 511 (66.5) 1.06 (0.90 to 1.26)
Yes, the same or more than before pregnancy 88 (67.7) 0.95 (0.64 to 1.40) 28 (21.5) 1.19 (0.74 to 1.90) 89 (68.5) 1.21 (0.81 to 1.82)
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weighted versus the risk of undertreated depression in
pregnancy.
In most regions, approximately 60–70% of women
reported use of at least one OTC medication during the
course of their pregnancies, mostly for pain conditions,
heartburn and upper airways disorders, indicating a sub-
stantially high rate of self-medication during pregnancy.
This estimate aligns with previous research carried out
in North America.17 Of note, self-medication with OTC
sympathomimetic nasal decongestants was more exten-
sive in Northern and Eastern Europe than in the
remaining regions; this could be explained by the time
of the year when the data collection was performed.
Region of residency was an important factor associated
with medication use during pregnancy. As also shown by
Cleary et al,36 we found that rates of medication use
among women originally from Eastern Europe and
South America were signiﬁcantly lower than those
observed in Western Europe, North America and
Australia. Such geographical differences could be due to
culture, variations in prenatal care assistance or access to
medications in the various regions and the related costs.
Women working as healthcare providers, consuming
alcohol during pregnancy or those already having chil-
dren were more likely to use short-term and OTC medi-
cations, possibly reﬂecting higher conﬁdence in
self-treatment and use of medications in general in the
former instance, and less anxiety for the pregnancy
outcome in the latter two instances.
Contrary to previous studies indicating an association
between higher maternal education and more prevalent
use of medication during pregnancy,14 17 23 we found
that lower education was associated with a higher use of
OTC medications as well as medication for chronic/
long-term disorders (30–50% increased risk). Results of
similar magnitude (30% increased risk) were also
observed by Olesen et al,37 whereas Stokholm et al38
identiﬁed a stronger association (2.3-fold increased risk)
between low maternal education and use of antibiotic
for respiratory tract infections during pregnancy. One
factor negatively associated with chronic/long-term
medication use was not having the ofﬁcial language of
the country of residency as mother tongue. This ten-
dency was detected in Western and Northern Europe,
raising concerns about the potential health risks for
immigrant women in these two regions. As shown by
Hämeen-Anttila et al,39 57% of pregnant women have
perceived information needs about medications during
pregnancy. Thus, identiﬁcation of potential users or
non-users of medication during pregnancy might be of
clinical relevance. Indeed, this may allow tailored
evidence-based information about medication safety or
outcome of suboptimal medication of severe medical
conditions in pregnancy.
Strengths and limitations
The main strength is that data collection was performed
uniformly across all participating countries, allowing for
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intercountry comparison of the prevalence of medica-
tion use during pregnancy. By quantifying the extent of
self-medication with OTC drugs and medication use
according to self-reported indication, it was possible to
determine the leading causes for medication use among
pregnant women. Categorisation of maternal character-
istics positively associated with the various types of medi-
cations used during pregnancy enabled us to identify
which groups of women are more likely to need infor-
mation about medication use during pregnancy. The
utilisation of an anonymous web-based questionnaire
enabled us to reach a large proportion of the birthing
population in several countries worldwide. However, we
cannot exclude the possibility that the women who
decided to participate in the study differed from the
general birthing population in other ways that our ana-
lysis could not control for. In most of the participating
countries, the study sample was large enough to warrant
calculation of prevalence estimates with a precision of
5%. However, less precise estimates were permitted by
the study sample in Austria, Iceland and the
Netherlands (precision of 9–11%), as well as in
Australia, Canada, Croatia, Serbia, Slovenia and the USA
(precision of 6–7%).
One main limitation of the study is the lack of validity
of the self-reported diagnoses. All disorders were self-
reported by the participants, and hence dependent on
the women’s perception of the medical condition.
Similarly, information about medication use during
pregnancy was dependent on the accuracy of the
women’s reporting and recall. For new mothers, data
were registered retrospectively; hence a risk of recall bias
cannot be ruled out. In speciﬁc countries (Australia,
Canada, France, Russia, the Netherlands and the USA),
the study sample was a small proportion of the general
birthing population; hence the generalisability of our
ﬁndings for these speciﬁc countries should be inter-
preted with caution.
The questionnaire was only available through Internet
websites; by using this kind of approach, a conventional
response rate cannot be calculated and a selection bias
of the target population cannot be ruled out. However,
recent epidemiological studies indicate reasonable valid-
ity of web-based recruitment methods.40 41 Also, the
penetration rate of the Internet either in households or
at work is relatively high among women in childbearing
age.42–46 Hence, the degree to which our ﬁndings can
be extrapolated to the target population is based on the
representativeness of the respondents to the general
birthing populations in each country. The sample in
each country had a somewhat higher educational level
than the general birthing populations. Such a limitation
might have led to an underestimation of the prevalence
of medication during pregnancy. Since many ailments
requiring pharmacotherapy occur in mid or late preg-
nancy, inclusion of women in the ﬁrst trimester of preg-
nancy in the total data material has somewhat inﬂated
the prevalence of non-users of medications during
pregnancy. Also, women with speciﬁc disorders or in
need of information about medication use during preg-
nancy might have been more likely to consult Internet
websites, and therefore participate in this study.
CONCLUSIONS
Use of medications for acute/short-term illnesses and
chronic/long-term disorders, as well as use of OTC med-
ications, was common during pregnancy. The extent of
medicated illnesses and types of medications used for
the different indications varied across the six regions.
This was especially relevant not only for acute/short-
term illnesses such as nausea and UTIs, but also for
chronic/long-term disorders such as hypothyroidism or
depression. Women with higher age or lower educa-
tional level, housewives or women with an unplanned
pregnancy were those most often reporting chronic/
long-term medication use, as opposed to immigrants res-
iding in Western and Northern Europe who reported
the least use of this medication category. Future research
should deﬁnitely focus on this speciﬁc group of women
and also address more insights into the outcome of sub-
optimal medication for severe conditions in pregnancy.
Author affiliations
1School of Pharmacy, University of Oslo, Oslo, Norway
2Department of Clinical Pharmacology, St Olav’s University Hospital,
Trondheim, Norway
3Department of Laboratory Medicine, Children’s and Women’s Health,
Norwegian University of Science and Technology, Trondheim, Norway
4School of Pharmacy, University of East Anglia, UK
5Northwest Medical Center for Drug Safety in Pregnancy & Lactation,
Northwest State Medical University n.a.I.I.Mechnikov, St Petersburg, Russia
6Department of Public Health and Community Medicine, The Sahlgrenska
Academy, University of Gothenburg, Gothenburg, Sweden
7The Motherisk Program, Division of Clinical Pharmacology and Toxicology,
The Hospital for Sick Children, University of Toronto, Toronto, Ontario,
Canada
8Faculty of Pharmacy, Medical University of Lublin, Lublin, Poland
9School of Pharmaceutical Sciences, University of Geneva and Lausanne,
Geneva, Switzerland
10Finnish Medicines Agency, Kuopio, Finland
11APHP, GH HUPS, Hop Antoine Béclère, Service Pharmacie, Clamart France
and Européenne de Formation pour les Pharmaciens, Paris, France
12Neuropediatric Unit, Children’s Hospital Srebrnjak, Zagreb, Croatia
13Department of Social Pharmacy and Pharmaceutical Legislation, Faculty of
pharmacy, University of Belgrade, Belgrade, Serbia
14MotherSafe, Royal Hospital for Women and University of NSW, Randwick,
Australia
15Clinical Institute of Medical Genetics, University Medical Centre Ljubljana,
Ljubljana, Slovenia
16Research Unit Human Teratogens, Institute for Cell Biology, Histology and
Embryology, Medical University of Graz, Graz, Austria
17Teratology Information Service (TIS), The Netherlands Pharmacovigilance
Centre Lareb, Den Bosch, The Netherlands
18Division of Mental Health, Norwegian Institute of Public Health, Oslo,
Norway
Acknowledgements The authors thank the Organisation of Teratology
Information Specialists (OTIS) and the European Network of Teratology
Information Services (ENTIS) Scientific Board who reviewed the study
protocol and all website providers who contributed to the recruitment phase.
They are grateful to all the participating women who took part in this study.
Lupattelli A, Spigset O, Twigg MJ, et al. BMJ Open 2014;4:e004365. doi:10.1136/bmjopen-2013-004365 9
Open Access
 group.bmj.com on February 17, 2014 - Published by bmjopen.bmj.comDownloaded from 
Contributors AL, OS and HN conceived the idea for the study and participated
in its design and coordination. AL drafted the manuscript and analysed the
data. MJT, KZ, ACM, MEM, MD, AP, KH-A, AR, RGJ, MO, DK, GR, HJ, AP and
IB contributed to data collection. All authors contributed to the interpretation
of the results and revised the manuscript critically for important intellectual
content. All the authors read and approved the final version of the
manuscript.
Funding This work was supported by the Norwegian Research Council grant
number 216771/F11 and by the Foundation for Promotion of Norwegian
Pharmacies and the Norwegian Pharmaceutical Society.
Competing interests None.
Ethics approval The study was approved by the Regional Ethics Committee,
Region South-East in Norway. Ethical approval or study notification to the
relevant national Ethics Boards was achieved in specific countries as required
by national legislation.
Provenance and peer review Not commissioned; externally peer reviewed.
Data sharing statement No additional data are available. Researchers can
apply for data access for subprojects within the overall aims of the main
study ‘The Multinational Medication Use in Pregnancy Study’.
Open Access This is an Open Access article distributed in accordance with
the Creative Commons Attribution Non Commercial (CC BY-NC 3.0) license,
which permits others to distribute, remix, adapt, build upon this work non-
commercially, and license their derivative works on different terms, provided
the original work is properly cited and the use is non-commercial. See: http://
creativecommons.org/licenses/by-nc/3.0/
REFERENCES
1. Committee on Ethics, American College of Obstetricians and
Gynecologists. ACOG Committee Opinion No. 377: research
involving women. Obstet Gynecol 2007;110:731–6.
2. Adam MP, Polifka JE, Friedman JM. Evolving knowledge of the
teratogenicity of medications in human pregnancy. Am J Med Genet
C Semin Med Genet 2011;157:175–82.
3. Briggs GG, Freeman RK, Yaffe SJ. Drugs in pregnancy and
lactation. [S.l.]: Lippincott Williams & Wilkins, 2011.
4. Mitchell AA, Gilboa SM, Werler MM, et al. Medication use during
pregnancy, with particular focus on prescription drugs: 1976–2008.
Am J Obstet Gynecol 2011;205:51 e1–8.
5. Odalovic M, Vezmar Kovacevic S, Ilic K, et al. Drug use before and
during pregnancy in Serbia. Int J Clin Pharm 2012;34:719–27.
6. Gagne JJ, Maio V, Berghella V, et al. Prescription drug use during
pregnancy: a population-based study in Regione Emilia-Romagna,
Italy. Eur J Clin Pharmacol 2008;64:1125–32.
7. Engeland A, Bramness JG, Daltveit AK, et al. Prescription drug use
among fathers and mothers before and during pregnancy. A
population-based cohort study of 106,000 pregnancies in Norway
2004–2006. Br J Clin Pharmacol 2008;65:653–60.
8. Bakker MK, Jentink J, Vroom F, et al. Drug prescription patterns before,
during and after pregnancy for chronic, occasional and
pregnancy-related drugs in the Netherlands. BJOG 2006;113:559–68.
9. Lacroix I, Hurault C, Sarramon MF, et al. Prescription of drugs during
pregnancy: a study using EFEMERIS, the new French database.
Eur J Clin Pharmacol 2009;65:839–46.
10. Malm H, Martikainen J, Klaukka T, et al. Prescription drugs during
pregnancy and lactation—a Finnish register-based study. Eur J Clin
Pharmacol 2003;59:127–33.
11. Daw JR, Hanley GE, Greyson DL, et al. Prescription drug use during
pregnancy in developed countries: a systematic review.
Pharmacoepidemiol Drug Saf 2011;20:895–902.
12. Rubin JD, Ferencz C, Loffredo C. Use of prescription and
non-prescription drugs in pregnancy. J Clin Epidemiol
1993;46:581–9.
13. McKenna L, McIntyre M. What over-the-counter preparations are
pregnant women taking? A literature review. J Adv Nurs
2006;56:636–45.
14. Odalovic M, Vezmar Kovacevic S, Nordeng H, et al. Predictors of
the use of medications before and during pregnancy. Int J Clin
Pharm 2013;35:408–16.
15. Martindale W, Sweetman SC. Martindale: the complete drug
reference. London: Pharmaceutical Press, 2011.
16. WHO Collaborating Centre for Drugs Statistics Methodology.
Guidelines for ATC classification and DDD assignment 2013. Oslo,
2012. http://www.whocc.no/atc_ddd_index/ (accessed 17 Mar 2012).
17. Refuerzo JS, Blackwell SC, Sokol RJ, et al. Use of over-the-counter
medications and herbal remedies in pregnancy. Am J Perinatol
2005;22:321–4.
18. Sawicki E, Stewart K, Wong S, et al. Medication use for chronic
health conditions by pregnant women attending an Australian
maternity hospital. Aust N Z J Obstet Gynaecol 2011;51:
333–8.
19. Hosmer DW, Lemeshow S. Applied logistic regression. New York:
Wiley-Interscience, 2000.
20. Nordeng H, Ystrøm E, Einarson A. Perception of risk regarding the
use of medications and other exposures during pregnancy. Eur J
Clin Pharmacol 2010;66:207–14.
21. Headley J, Northstone K, Simmons H, et al. Medication use during
pregnancy: data from the Avon longitudinal study of parents and
children. Eur J Clin Pharmacol 2004;60:355–61.
22. [No authors listed]. Medication during pregnancy: an intercontinental
cooperative study. Collaborative Group on Drug Use in Pregnancy
(C.G.D.U.P.). Int J Gynaecol Obstet 1992;39:185–96.
23. Donati S, Baglio G, Spinelli A, et al. Drug use in pregnancy among
Italian women. Eur J Clin Pharmacol 2000;56:323–8.
24. Henry A, Crowther C. Patterns of medication use during and prior to
pregnancy: the MAP study. Aust N Z J Obstet Gynaecol
2000;40:165–72.
25. Marín G, Cañas M, Homar C, et al. Uso de fármacos durante el
período de gestación en embarazadas de Buenos Aires, Argentina.
Rev salud pública 2010;12:722–31.
26. European Centre for Disease Prevention and Control. Surveillance
of antimicrobial consumption in Europe, 2010. Stockholm: ECDC,
2013.
27. Smith J, Refuerzo J, Ramin S. Treatment and outcome of nausea
and vomiting of pregnancy. In: Basow D. ed UpToDate. Waltham,
MA (accessed 8 Jun 2013).
28. Gadsby R, Barnie-Adshead T, Sykes C. Why won’t doctors
prescribe antiemetics in pregnancy? BMJ 2011;343:d4387.
29. Raymond SH. A survey of prescribing for the management of
nausea and vomiting in pregnancy in Australasia. Aust N Z J Obstet
Gynaecol 2013;53:358–62.
30. Ross DS. Hypothyroidism during pregnancy: clinical manifestations,
diagnosis, and treatment. In: Basow DS. ed UpToDate. Waltham,
MA (accessed 8 Jun 2013).
31. Lewis AJ, Bailey C, Galbally M. Anti-depressant use during
pregnancy in Australia: findings from the longitudinal study of
Australian children. Aust N Z J Public Health 2012;
36:487–8.
32. Petersen I, Gilbert RE, Evans SJ, et al. Pregnancy as a major
determinant for discontinuation of antidepressants: an analysis of
data from the Health Improvement Network. J Clin Psychiatry
2011;72:979–85.
33. Grigoriadis S, VonderPorten EH, Mamisashvili L, et al.
Antidepressant exposure during pregnancy and congenital
malformations: is there an association? A systematic review and
meta-analysis of the best evidence. J Clin Psychiatry 2013;74:
e293–308.
34. Grigoriadis S, Vonderporten EH, Mamisashvili L, et al. Prenatal
exposure to antidepressants and persistent pulmonary hypertension
of the newborn: systematic review and meta-analysis. BMJ
2014;348:f6932.
35. Grigoriadis S, VonderPorten EH, Mamisashvili L, et al. The effect of
prenatal antidepressant exposure on neonatal adaptation: a
systematic review and meta-analysis. J Clin Psychiatry 2013;74:
e309–20.
36. Cleary BJ, Butt H, Strawbridge JD, et al. Medication use in early
pregnancy-prevalence and determinants of use in a prospective
cohort of women. Pharmacoepidemiol Drug Saf 2010;19:
408–17.
37. Olesen C, Thrane N, Henriksen TB, et al. Associations between
socio-economic factors and the use of prescription medication
during pregnancy: a population-based study among 19,874 Danish
women. Eur J Clin Pharmacol 2006;62:547–53.
38. Stokholm J, Schjorring S, Pedersen L, et al. Prevalence and
predictors of antibiotic administration during pregnancy and birth.
PLoS ONE 2013;8:e82932.
39. Hämeen-Anttila K, Jyrkkä J, Enlund H, et al. Medicines information
needs during pregnancy: a multinational comparison. BMJ Open
2013;3 :pii:e002594.
40. Ekman A, Dickman P, Klint Å, et al. Feasibility of using web-based
questionnaires in large population-based epidemiological studies.
Eur J Epidemiol 2006;21:103–11.
10 Lupattelli A, Spigset O, Twigg MJ, et al. BMJ Open 2014;4:e004365. doi:10.1136/bmjopen-2013-004365
Open Access
 group.bmj.com on February 17, 2014 - Published by bmjopen.bmj.comDownloaded from 
41. van Gelder MM, Bretveld RW, Roeleveld N. Web-based questionnaires:
the future in epidemiology? Am J Epidemiol 2010;172:1292–8.
42. Seybert H. Internet use in households and by individuals in 2011.
Eurostat Statistics in focus, 2011. http://epp.eurostat.ec.europa.eu/
cache/ITY_OFFPUB/KS-SF-11–066/EN/KS-SF-11-066-EN.PDF
(accessed 13 Nov 2012).
43. Internet World Stats. Usage and population statistics. 2012. http://
www.internetworldstats.com/ (accessed 13 Nov 2012).
44. Australian Bureau of Statistics. Household use of information
technology. Australia, 2010–2011. http://www.abs.gov.au/ausstats/
abs@.nsf/Latestproducts/8146.0Main.Features12010-11?
opendocument&tabname=Summary&prodno=8146.
0&issue=2010-11&num=&view= (accessed 13 Nov 2012).
45. Statistics Canada. Individual internet use and e-commerce (2010).
2011. http://www.statcan.gc.ca/daily-quotidien/111012/
dq111012a-eng.htm (accessed 13 Nov 2012).
46. United States Census Bureau. The 2012 statistical abstract.
Information & Communications: Internet Publishing and
Broadcasting and Internet Usage, 2010. http://www.census.gov/
compendia/statab/cats/information_communications/internet_
publishing_and_broadcasting_and_internet_usage.html (accessed
13 Nov 2012).
Lupattelli A, Spigset O, Twigg MJ, et al. BMJ Open 2014;4:e004365. doi:10.1136/bmjopen-2013-004365 11
Open Access
 group.bmj.com on February 17, 2014 - Published by bmjopen.bmj.comDownloaded from 
doi: 10.1136/bmjopen-2013-004365
 2014 4: BMJ Open
 
A Lupattelli, O Spigset, M J Twigg, et al.
 
study
cross-sectional, multinational web-based 
Medication use in pregnancy: a
 http://bmjopen.bmj.com/content/4/2/e004365.full.html
Updated information and services can be found at: 
These include:
Data Supplement
 http://bmjopen.bmj.com/content/suppl/2014/02/17/bmjopen-2013-004365.DC1.html
"Supplementary Data"
References
 http://bmjopen.bmj.com/content/4/2/e004365.full.html#ref-list-1
This article cites 34 articles, 2 of which can be accessed free at:
Open Access
non-commercial. See: http://creativecommons.org/licenses/by-nc/3.0/
terms, provided the original work is properly cited and the use is
work non-commercially, and license their derivative works on different 
license, which permits others to distribute, remix, adapt, build upon this
Creative Commons Attribution Non Commercial (CC BY-NC 3.0) 
This is an Open Access article distributed in accordance with the
service
Email alerting
the box at the top right corner of the online article.
Receive free email alerts when new articles cite this article. Sign up in
Notes
 http://group.bmj.com/group/rights-licensing/permissions
To request permissions go to:
 http://journals.bmj.com/cgi/reprintform
To order reprints go to:
 http://group.bmj.com/subscribe/
To subscribe to BMJ go to:
 group.bmj.com on February 17, 2014 - Published by bmjopen.bmj.comDownloaded from 
